目的 探讨双黄连注射液联合哌拉西林钠他唑巴坦钠治疗社区获得性肺炎的临床效果。方法 选取2020年10月-2023年9月华北医疗健康集团峰峰总医院收治的86例社区获得性肺炎患者,按随机数字表法将所有患者分为对照组和治疗组,每组各43例。对照组静脉滴注注射用哌拉西林钠他唑巴坦钠,将4.5 g本品以稀释液充分溶解后,立即加入100 mL5%葡萄糖注射液中,每次给药时间 ≥ 30 min,2次/d。治疗组在对照组治疗基础上静脉滴注双黄连注射液,按体质量1 mL/kg加入250 mL 5%葡萄糖注射液中,1次/d。两组疗程均为7 d。观察两组临床疗效,比较两组临床表现消失时间及治疗前后氧合指数(OI)、CURB-65评分、红细胞沉降率(ESR)、中性粒细胞与淋巴细胞比值(NLR)及血清淀粉样蛋白A(SAA)、降钙素原(PCT)。结果 治疗后,治疗组总有效率是97.67%,显著高于对照组的81.40%(P<0.05)。治疗组发热、咳嗽、咯痰、胸闷痛及肺部啰音消失时间较之对照组显著缩短(P<0.05)。治疗后,两组OI均显著增高,而CURB-65评分均显著降低(P<0.05);且治疗后,治疗组OI显著高于对照组,CURB-65评分显著低于对照组(P<0.05)。治疗后,两组ESR、NLR及血清SAA、PCT水平治疗后均显著下降(P<0.05);治疗后,治疗组患者ESR、NLR及血清SAA、PCT水平低于对照组(P<0.05)。结论 双黄连注射液联合哌拉西林钠他唑巴坦钠治疗社区获得性肺炎效果确切,能有效促进患者临床表现消除及呼吸功能改善,抑制机体炎症状态及肺部感染程度,利于加快病情缓解,值得临床推广应用。

Objective To explore the clinical efficacy of Shuanghuanglian Injection combined with piperacillin sodium and tazobactam sodium in treatment of community acquired pneumonia. Methods A total of 86 patients with community-acquired pneumonia admitted to Fengfeng General Hospital of North China Medical and Health Group from October 2020 to September 2023 were selected and divided into control group and treatment group according to random number table method, with 43 cases in each group. Patients in the control group were iv administered with Piperacillin Sodium and Tazobactam Sodium for injection, after fully dissolving 4.5 g of the product with diluent, immediately added it into 5% glucose injection100 mL, each administration time ≥ 30 min, twice daily. Patients in the treatment group were iv administered with Shuanghuanglian Injection on the basis of the control group, added 5% glucose injection250 mL at the weight of 1 mL/kg, once daily. The treatment course of both groups was 7 d. The clinical effects of the two groups were observed, and the disappearance time of clinical manifestations, oxygenation index (OI), CURB-65 score, erythrocyte settlement rate (ESR), neutrophil to lymphocyte ratio (NLR), serum amyloid A (SAA) and procalcitonin (PCT) were compared between two groups. Results After treatment, the total effective rate of the treatment group was 97.67%, which was significantly higher than that of control group (81.40%, P < 0.05). The disappearance time of fever, cough, phlegm, chest pain, and lung rales in treatment group was significantly shorter than that in control group (P < 0.05). After treatment, OI was significantly increased in both groups, but CURB-65 score was significantly decreased in both groups (P < 0.05). After treatment, OI in treatment group was significantly higher than that in control group, but CURB-65 score was significantly lower than that in control group (P < 0.05). After treatment, the levels of ESR, NLR and serum SAA and PCT in both groups were significantly decreased (P < 0.05). After treatment, the levels of ESR, NLR, SAA, and PCT in the treatment group were lower than those in control group (P < 0.05). Conclusion Shuanghuanglian Injection combined with piperacillin sodium and tazobactam sodium has a definite effect in treatment of community acquired pneumonia, and can effectively promote the elimination of clinical manifestations and the improvement of respiratory function, inhibit the inflammatory state of the body and the degree of lung infection, and help accelerate the remission of the disease, which is worthy of clinical promotion and application.

R974

邯郸市科技计划项目（1523108125）